Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.76 |
| ▸ | JAK3 | P52333 | 3/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131418 | 0.98 | EGFR (0.82) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL17538502 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL19283327 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2129464 | 0.91 | EGFR (0.81) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2544071 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2508012 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL2510049 | 0.90 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17498548 | 0.90 | EGFR (0.81) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL17498545 | 0.90 | EGFR (0.81) | EGFRERBB2ERBB4JAK3KDR | |
| SCHEMBL2512053 | 0.90 | EGFR (0.81) | EGFRERBB2ERBB4JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445885-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | Medolution Limited (CN) | 2012-05-02 | — | — | EP | claimed |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MEDOLUTION LIMITED (US) | 2012-04-26 | — | — | US | claimed |
| WO-2010151710-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | MEDOLUTION LIMITED (CN) | 2010-12-29 | — | — | WO | claimed |
| US-8748453-B2 | Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof | MEDOLUTION LIMITED (HK) | 2014-06-10 | — | — | US | disclosed |
| EP-2445885-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | Medolution Limited (CN) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MEDOLUTION LIMITED (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010151710-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | MEDOLUTION LIMITED (CN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MAP4K2, MAP3K7, MAP3K1 | EGFR 1263/4885ERBB2 464/4885ERBB4 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.